Hironori Takeuchi

Prof. Hironori Takeuchi

hospital pharmacy, Tokyo Medical University Hospital

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2005 in Transplantation Proceedings
Verified
Journal Article
Closed access
TIT. Iwahori
T. Iwahori
HTHironori Takeuchi
Hironori Takeuchi
NMN. Matsuno
N. Matsuno
YJY. Johjima
Y. Johjima
OKO. Konno
O. Konno
KOK. Oka
K. Oka

24 May 2005 in Transplantation Proceedings
Verified
Journal Article
Closed access
HTHironori Takeuchi
Hironori Takeuchi
KOK. Okuyama
K. Okuyama
OKO. Konno
O. Konno
YJY. Jojima
Y. Jojima
IAI. Akashi
I. Akashi
KOK. Oka
K. Oka

13 April 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MOMasaaki Okihara
Masaaki Okihara
HTHironori Takeuchi
Hironori Takeuchi
YKYukiko Kikuchi
Yukiko Kikuchi
IAIsao Akashi
Isao Akashi
YKYu Kihara
Yu Kihara
俊平俊 彦 平野
俊 彦 平野
Recently, steroid reduction/withdrawal regimens have been attempted to minimize the side effects of steroids in renal transplantation. However, some recipients have experienced an increase/resumption of steroid administrations and acute graft rejection (AR). Therefore, we investigated the relationship between the individual lymphocyte sensitivity to steroids and the clinical outcome after steroid reduction/withdrawal. We cultured peripheral blood mononuclear cells (PBMCs) isolated from 24 recipients with concanavalin A (Con A) in the presence of methylprednisolone (MPSL) or cortisol (COR) for four days, and the 50% of PBMC proliferation (IC50) values and the PBMC sensitivity to steroids were calculated. Regarding the experience of steroid increase/resumption and incidence of AR within one year of steroid reduction/withdrawal, the IC50 values of these drugs before transplantation in the clinical event group were significantly higher than those in the event-free group. The cumulative incidence of steroid increase/resumption and AR in the PBMC high-sensitivity groups to these drugs before transplantation were significantly lower than those in the low-sensitivity groups. These observations suggested that an individual’s lymphocyte sensitivity to steroids could be a reliable biomarker to predict the clinical outcome after steroid reduction/withdrawal and to select the patients whose dose of steroids can be decreased and/or withdrawn after transplantation.